Aclaris 制药 ACRS
$3.90 +$0.29 (+8.03%)
休市 · Nov 6, 10:00 pm ET · 最新盘后价 $3.90 0.00%
开盘$3.62
昨收$3.61
当日区间$3.61 – $3.98
成交量3.53M
市值$618.59M
市盈率（TTM）–
股息率–
ACRS 相关新闻
匹配 Aclaris Therapeutics 或代码 ACRS 的头条新闻，按最新排序。
- CCORF Initiates Aclaris Therapeutics(ACRS.US) With Buy Rating, Announces Target Price $10
- Craig-Hallum Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $10
- H.C. Wainwright Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $16
- LifeSci Capital Initiates Aclaris Therapeutics(ACRS.US) With Buy Rating, Announces Target Price $13
- Wedbush Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $10
- Oppenheimer Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $10
- Guggenheim Initiates Aclaris Therapeutics(ACRS.US) With Buy Rating, Announces Target Price $12
- Piper Sandler Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Raises Target Price to $11 正面
- Guggenheim Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $12
- Wedbush Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Raises Target Price to $10 正面
- Oppenheimer Initiates Aclaris Therapeutics(ACRS.US) With Buy Rating, Announces Target Price $10
- Piper Sandler Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $11
- CCORF Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Raises Target Price to $13 正面
- Guggenheim Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $12
- H.C. Wainwright Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $16
暂无评论——快来第一个聊聊 ACRS。
登录后参与讨论。